AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9023068
Drug: Individual Drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Drug Counseling (IDC)
Trial: 25422247
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia combined with SGB (0.12 mL/kg 1% lidocaine 10 min before induction)
Trial: 25422247
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (group N)
Trial: 22500884
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg) + Bicalutamide (50 mg for 28 days)
Trial: 17623816
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg for 30 days)
Trial: 2910782
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cisplatin 50 mg/m2 over 24 hr
Trial: 2910782
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion of cisplatin 50 mg/m2 at a rate of 1 mg/min
Trial: 16015688
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment after 6 months
Trial: 12453861
Drug: IL‐2 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐2 9 MU subcutaneously twice daily on days 4‐8 and 25‐29, and once daily on days 11‐15 and 32‐36; IFN‐alpha‐2b 5 MU subcutaneously on days 1‐3 and then daily to day 43; Histamine 1 mg subcutaneously twice daily starting on day 4
Trial: 7856295
Drug: Aerosol inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol inactivated split influenza virus vaccine
Trial: 7856295
Drug: Cold-adapted reassortant
RxNorm normalized name: human-bovine reassortant rotavirus strain G4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted reassortant live influenza virus vaccine
Trial: 7856295
Drug: Mucosal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucosal administration of inactivated influenza virus vaccine
Trial: 2536803
Drug: Two-hour infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-hour infusion of cisplatin
Trial: 2536803
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion of cisplatin
Trial: 1060146
Drug: Active immunotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy after chemoradiotherapy
Trial: 1060146
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no active immunotherapy)
Trial: 1060146
Drug: Immunotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy after chemotherapy
Trial: 1060146
Drug: Immunotherapy before
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy before chemotherapy
Trial: 11473870
Drug: Lactated Ringers
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringers solution (RL), n = 21
Trial: 31315885
Drug: Repeated immunization
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated immunization with a Listeria monocytogenes‐based vaccine encoding for mesothelin in combination with a GM‐CSF‐transfected allogeneic pancreatic cell vaccine
Trial: 29648860
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (1‐hour video; n = 10)
Trial: 20416137
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) consisting of exposure and response prevention (EX/RP)
Trial: 16103696
Drug: Hand rubbing
RxNorm normalized name: ALCOHOL 0.8 TOPICAL SPRAY [Hand Rub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand rubbing with alcohol-based solutions
Trial: 12482009
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program involving individualized health promotion by a research pharmacist with monthly appointments for 6 months.
Trial: 7657446
Drug: 4% nicotinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% nicotinamide gel
Trial: 2697239
Drug: Labetalol 10
RxNorm normalized name: HCTZ 25/LABETALOL 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 10 mg
Trial: 2697239
Drug: Labetalol 5
RxNorm normalized name: LABETALOL 5MG/ML INJ CARPUJECT 4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 5 mg
Trial: 31543950
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone treatment (MHT) started within 5 to 10 years of menopause
Trial: 31543950
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment (ET) for women undergoing premature menopause
Trial: 31543950
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone treatment (MHT) for normal women
Trial: 26413574
Drug: 1500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day Korean red ginseng for 4 weeks
Trial: 26413574
Drug: 3000 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg/day Korean red ginseng for 4 weeks
Trial: 26413574
Drug: 160 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/day Ginkgo biloba extract for 4 weeks
Trial: 22077928
Drug: Soy isolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isolate protein supplement (24 g daily for 8 weeks)
Trial: 22077928
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein supplement (24 g daily for 8 weeks)
Trial: 19917449
Drug: Beta-glucan (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan (5.5 g)
Trial: 19917449
Drug: Beta-glucan (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan (2.2 g to 5.5 g)
Trial: 19917449
Drug: Beta-glucan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan (various doses)
Trial: 17030521
Drug: Caldaret 57.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caldaret 57.5 mg (lower dose)
Trial: 17030521
Drug: Caldaret 172.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caldaret 172.5 mg (higher dose)
Trial: 8858533
Drug: Chemotherapy (combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (combinations of Adriamycin and Dacarbazine or Ifosfamide and Mesna)
Trial: 8858533
Drug: Immunotherapy (interferon‐alpha)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (interferon‐alpha)
Trial: 6391162
Drug: Low-sucrose diet
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-sucrose diet (less than 3 g of sucrose)
Trial: 6391162
Drug: High-sucrose diet
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-sucrose diet (220 g of sucrose)
Trial: 6391162
Drug: Intermediate-sucrose diet
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate-sucrose diet (120 g of sucrose)
Trial: 6391162
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (120 g of sucrose and 50 percent carbohydrate)
Trial: 31986325
Drug: Topical ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ozone therapy (ozone hydrotherapy followed by ozonated oil)
Trial: 27741414
Drug: Topical ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ozone therapy
Trial: 22153696
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids 2 g daily for 2 months
Trial: 22153696
Drug: Fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160 mg daily for 2 months
Trial: 7036726
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg and 240 mg
Trial: 29463913
Drug: Oxycodone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5.0 mg
Trial: 29463913
Drug: Oxycodone 2.5
RxNorm normalized name: oxycodone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 2.5 mg + active cannabis (5.6% THC)
Trial: 29463913
Drug: Oxycodone 2.5
RxNorm normalized name: oxycodone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 2.5 mg
Trial: 29463913
Drug: Oxycodone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone + cannabis
Trial: 20142658
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) at a median dose of 81.5 microg/kg
Trial: 18566863
Drug: Specific oral
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific oral anticoagulation treatment educational program
Trial: 16629421
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (IFNbeta-1a, Avonex) 60 microg weekly intramuscular injections for 24 months
Trial: 14762699
Drug: Iodine-131 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-131 therapy (1.8-10.4 GBq single activity, 5.5-43.7 GBq total activity) after total thyroidectomy and lymph node dissection if applicable
Trial: 4039155
Drug: Flupirtine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine (100 mg, 3 consecutive doses)
Trial: 4039155
Drug: Pentazocine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (50 mg, single dose)
Trial: 2903762
Drug: Mifentidine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifentidine 20 mg
Trial: 2906876
Drug: Mifentidine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifentidine 40 mg
Trial: 2906876
Drug: Mifentidine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifentidine 80 mg
Trial: 29614679
Drug: Composite supplement
RxNorm normalized name: DRESSING,COMPOSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite supplement containing astaxanthin and sesamin (AS)
Trial: 24563922
Drug: Chloroprocaine (CP)
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroprocaine (CP) 40 mg intrathecally with 500 ml pre-load (CP+)
Trial: 24563922
Drug: Chloroprocaine (CP)
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroprocaine (CP) 40 mg intrathecally without pre-load (CP−)
Trial: 24563922
Drug: Lidocaine (L)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (L) 60 mg intrathecally with 500 ml pre-load (L+)
Trial: 24563922
Drug: Lidocaine (L)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (L) 60 mg intrathecally without pre-load (L−)
Trial: 14633959
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus somatostatin 250 microg given immediately after diagnostic cholangiopancreatography
Trial: 10966906
Drug: Glucose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (50 g carbohydrate)
Trial: 10966906
Drug: Potatoes (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potatoes (50 g carbohydrate)
Trial: 10966906
Drug: Barley (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barley (50 g carbohydrate)
Trial: 8470531
Drug: Scopolamine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (two pieces of Scopoderm-TTS patches)
Trial: 3511703
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet combined with antiandrogenic therapy (cyproterone acetate, 50 mg/day, plus ethinyl estradiol, 0.05 mg/day)
Trial: 3511703
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet without antiandrogenic therapy
Trial: 20413988
Drug: Probiotic Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Escherichia coli strain administered (1 mL within 48 hours after birth, then 3 times a week for 4 weeks)
Trial: 18687167
Drug: Amino-bisphosphonates treatment
RxNorm normalized name: (4-amino-1-hydroxybutylidene)bisphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino-bisphosphonates treatment
Trial: 1488514
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg (t.i.d.)
Trial: 6416184
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MMC and Futraful
Trial: 28193189
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose DHA supplementation (1000 mg DHA/d)
Trial: 28193189
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (200 mg DHA/d from prenatal supplement)
Trial: 19796455
Drug: Dutasteride 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 3.5 mg and bicalutamide 50 mg once daily
Trial: 19796455
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and bicalutamide 50 mg once daily
Trial: 8095008
Drug: Later zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Later zidovudine therapy
Trial: 8095008
Drug: Masked therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masked therapy continuation
Trial: 8095008
Drug: Unmasked treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmasked treatment and follow-up
Trial: 3680580
Drug: Nalmefene 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 50 mg
Trial: 3680580
Drug: Nalmefene 100
RxNorm normalized name: nalmefene 100 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 100 mg
Trial: 3680580
Drug: Nalmefene 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 200 mg
Trial: 3680580
Drug: Nalmefene 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 300 mg
Trial: 3680580
Drug: Nalmefene 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 20 mg q12h for 7 days
Trial: 26509991
Drug: Laser-Lok implants
RxNorm normalized name: Lokara
DrugBank: Desonide (DB01260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laser-Lok implants (LL)
Trial: 26509991
Drug: Non-Laser-Lok implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Laser-Lok implants (NLL)
Trial: 23398493
Drug: Combined cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive behavioral therapy (CBT)
Trial: 22026413
Drug: Intraarticular ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular ropivacaine infusion (0.5%, 2 mL/h)
Trial: 22026413
Drug: Extraarticular ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraarticular ropivacaine infusion (0.5%, 2 mL/h)
Trial: 17297828
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 1 mL of saline (Group II)
Trial: 17297828
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 150 microg of clonidine (Group IV)
Trial: 17297828
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 1% mepivacaine with 150 microg of clonidine plus 4mL of saline (Group III)
Trial: 17297828
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 1% mepivacaine with adrenaline plus 5 mL of saline (Group I - Control)
Trial: 11119051
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) as add-on therapy
Trial: 2586439
Drug: Chemo-immunotherapy (CDDP+VDS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy (CDDP+VDS, IL2+LAK cells)
Trial: 2586439
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro stimulated LAK cells (St-LAK) administered locally
Trial: 2586439
Drug: LAK-BAI (bronchial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAK-BAI (bronchial arterial infusion) combined with radiation therapy
Trial: 2586439
Drug: Chemotherapy (CDDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CDDP + VDS)
Trial: 31475938
Drug: Manual posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual posterior capsule stretching (Group 2, n=27)
Trial: 31475938
Drug: Combined application
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined application of scapular mobilization and manual posterior capsule stretching (n=54)
Trial: 29214925
Drug: ISO +
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISO + EXE (100 mg of isoflavone and exercise)
Trial: 25994188
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection loading (100 ml 5% glucose injection + 50 ml Shenfu injection)
Trial: 25994188
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (150 ml 5% glucose injection)
Trial: 24952857
Drug: NT‐proBNP-guided treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP-guided treatment
Trial: 11943102
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no effect on H. pylori infection)
Trial: 9649995
Drug: Vecuronium (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.12 mg kg‐1)
Trial: 8543493
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g every 8 h (n = 77)
Trial: 8543493
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g and metronidazole 500 mg every 8 h (n = 83)
Trial: 6797288
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (group II)
Trial: 29153415
Drug: Formoterol (FOM)
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol (FOM) DPI (9 μg via a Turbuhaler®)
Trial: 25986615
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 (1×10^8 CFU for five days) + Oral Rehydration Solution (ORS)
Trial: 29941406
Drug: Fixed-dose bictegravir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide
Trial: 24752322
Drug: PVC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVC group (propofol infusion via a 1‐m PVC infusion extension tube)
Trial: 22261236
Drug: Four treatment
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four treatment regimens for NGU
Trial: 18506317
Drug: Dexmedetomidine Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg), plus dexmedetomidine, 1 mg x kg‐1
Trial: 18506317
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg)
Trial: 8757002
Drug: Linomide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linomide (2.5 mg daily)
Trial: 21409494
Drug: Conivaptan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan (20 mg single dose)